Â鶹ӳ»­

As a medical student at Baylor College of Medicine, Steve Meltzer traveled past MD Anderson many times. However, he never thought he would one day be a patient here.

In October 2020, just six weeks before he planned to retire from his long career as a physician, he was simultaneously diagnosed with both T-cell acute lymphoblastic leukemia (T-ALL) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a rare and aggressive blood cancer that often transforms into acute leukemia. The disease impacts approximately 500 to 1,000 people in the U.S. each year. T-ALL is also an acute leukemia that begins in the bone marrow and lymph nodes and can spread to other organs.

For Steve, the diagnosis came as a surprise, and it took several tests and doctors¡¯ appointments to explain a mysterious mass on his clavicle.

An ear, nose and throat doctor had encouraged him to get a biopsy of the mass, but that testing didn¡¯t find anything. ¡°My white blood cell count was very low, but there was no indication of cancer,¡± Steve recalls. ¡°Later, I went to a hematologist to repeat more blood work and do a bone marrow aspiration, which also came back negative.¡±

By this time, the mass had grown slightly. His doctors were stumped. As a physician himself, so was Steve.

A dual diagnosis: BPDCN and T-cell acute lymphoblastic leukemia

During a routine skin screening with his dermatologist, she saw the mass and insisted he get a third opinion. This time a surgeon removed the mass, examined it and determined it was BPDCN and T-ALL.

¡°It¡¯s hard to know when the mass really started. Doctors were stumped until the mass was finally removed,¡± Steve says. ¡°This type of cancer is so rare that there are few doctors who treat it, but my hematologist found Dr. Pemmaraju and said go to MD Anderson.¡± Meltzer met with , a leukemia expert specializing in BPDCN.

BPDCN is often misdiagnosed since it is so rare and shares symptoms of other blood cancers.

¡°I¡¯m glad he was able to get to us when he did because we were able to assess him and get a treatment plan going almost immediately,¡± Pemmaraju says. ¡°We initially wanted to enroll him in a clinical trial that was ongoing at the time; however, because he also had heart disease, we had to discuss alternatives.¡±

Doctors personalize BPDCN and T-cell acute lymphoblastic leukemia treatment

Pemmaraju worked with oncocardiologist , and stem cell transplant specialist , to examine Steve¡¯s case. They determined chemotherapy followed by stem cell transplant was the best route for him and would ensure his heart would withstand treatment.

The chemotherapy he received was an innovative hybrid regimen incorporating systemic alternating multi-agent chemotherapy and central nervous system prophylactic chemotherapy developed by Pemmaraju and , for Steve¡¯s unique case of extremely rare, life-threatening dual cancers and heart disease. The personalized, innovative regimen was based on chemotherapy principles of multi-agent delivery that Kantarjian originally described and pioneered over the past several decades. The chemotherapy and stem cell transplant were both successful. 

Gratitude for the experts

Four years later, both cancers are in remission, and Steve has tremendous gratitude for all the doctors who played a role in determining his diagnosis and treating him successfully.

¡°I¡¯ve been able to enjoy retirement with my wife, watch television together for what feels like the first time in decades, work on my old jalopies, and spend time with our friends and family,¡± Steve says. ¡°I relinquished a lot of control during my treatment at MD Anderson, which is rare for me as a physician. I trusted the experts, and they did not let me down.¡±

or call 1-877-632-6789.